Oncology News Central

2 days ago | oncologynewscentral.com | Neil Osterweil

For patients with resectable non-small cell lung cancer (NSCLC) who have EGFR mutations, treatment with osimertinib (Tagrisso) before surgery with or without chemotherapy was associated with statistically significant improvements in major pathologic responses. Findings from the NeoADAURA trial were presented in an oral abstract session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting by Jamie E. Chaft, MD, from Memorial Sloan Kettering Cancer Center in New York City.

3 days ago | oncologynewscentral.com | Neil Osterweil

Data from the CheckMate 816 trial, published in The New England Journal of Medicine (NEJM) in 2022, showed that adding the immune checkpoint inhibitor nivolumab to neoadjuvant chemotherapy resulted in improved pathologic complete responses (pCRs) and event-free survival (EFS) for patients with resectable non-small cell lung cancer (NSCLC).

3 days ago | oncologynewscentral.com | Tara Haelle

Niraparib with abiraterone acetate plus prednisone (AAP) reduced the risk for radiographic progression in patients with metastatic castration-sensitive prostate cancer (mCSPC) who had homologous recombination repair (HRR) gene alterations. Findings from the phase 3 randomized, controlled AMPLITUDE trial were presented as part of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (LBA5006).

5 days ago | oncologynewscentral.com | Aaron Tallent

Chemotherapy‑induced thrombocytopenia (CIT) is a common adverse event (AE) that can negatively affect care. Now, results from the phase 3 RECITE trial show that romiplostim (Nplate) is effective in treating it in patients with a gastrointestinal (GI) cancer who are receiving oxaliplatin-based chemotherapy. Researchers presented the findings at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and say that the data offer a potential new option for managing CIT (Abstract 12007).

5 days ago | oncologynewscentral.com | Neil Osterweil

An updated analysis from the CheckMate 77T trial comparing perioperative nivolumab (Opdivo) to placebo in patients with resectable non-small cell lung cancer (NSCLC) show that the event-free survival (EFS) benefit seen with the immune checkpoint inhibitor in earlier analyses continues with longer follow-up, now nearing 5 years.